The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?

(2012) Rashmi R. Shah   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes

(2011) Fernando Ovalle   CLINICAL THERAPEUTICS

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

(2011) Sherwyn L. Schwartz et al.   Diabetes Technology & Therapeutics

Seven useful designs

(2011) Steven A. Julious   PHARMACEUTICAL STATISTICS

Overview of Newer Agents: Where Treatment Is Going

(2010) Ralph A. DeFronzo   AMERICAN JOURNAL OF MEDICINE

Drug- and non-drug-associated QT interval prolongation

(2010) Charlotte Van Noord et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Hypoglycemia, Diabetes, and Cardiovascular Events

(2010) C. V. Desouza et al.   DIABETES CARE

Dapagliflozin: more than just another oral glucose-lowering agent?

(2010) Niki Katsiki et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sample Size Calculations for Crossover Thorough QT Studies: Satisfaction of Regulatory Threshold and Assay Sensitivity

(2010) Suraj P. Anand et al.   Journal of Biopharmaceutical Statistics

Effect of Number of Replicate Electrocardiograms Recorded at Each Time Point in a Thorough QT Study on Sample Size and Study Cost

(2010) Mili Natekar et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation

(2010) Robert Schall et al.   PHARMACEUTICAL STATISTICS

Mixed models for data from thorough QT studies: Part 2. One-step assessment of conditional QT prolongation

(2010) Robert Schall   PHARMACEUTICAL STATISTICS

Statistical models for heart rate correction of the QT interval

(2010) Arne Ring   STATISTICS IN MEDICINE

The use of baseline covariates in crossover studies

(2009) Michael G. Kenward et al.   BIOSTATISTICS

Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005

(2009) Sarah Rosner Preis et al.   CIRCULATION

Period Correction of the QTc of Moxifloxacin With Multiple Predose Baseline ECGs Is the Least Variable of 4 Methods Tested

(2009) Xiaoping Zhang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

(2009) Cyrus DeSouza et al.   NATURE REVIEWS DRUG DISCOVERY

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

(2008) DM Bloomfield et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Sample Size Calculations in Thorough QT Studies

(2008) Lu Zhang et al.   Journal of Biopharmaceutical Statistics

Testing for Positive Control Activity in a Thorough QTc Study∗

(2008) Joanne Zhang   Journal of Biopharmaceutical Statistics

Performance Characteristics for Some Typical QT Study Designs Under the ICH E-14 Guidance

(2008) Matthew M. Hutmacher et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Concentration-QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review

(2007) Christin E. Garnett et al.   JOURNAL OF CLINICAL PHARMACOLOGY